ProfileGDS5678 / 1443721_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 70% 72% 67% 74% 72% 71% 72% 70% 70% 69% 70% 71% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.715762
GSM967853U87-EV human glioblastoma xenograft - Control 24.394470
GSM967854U87-EV human glioblastoma xenograft - Control 34.5345672
GSM967855U87-EV human glioblastoma xenograft - Control 44.1252667
GSM967856U87-EV human glioblastoma xenograft - Control 54.8100374
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4835372
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4784471
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.5166272
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3902870
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3400770
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2623169
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3926670
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.5039271
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4180871